A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2015.10.012PMID 26724641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

  2015cited by this paper
• Clinical management of breast cancer heterogeneity

  2015cited by this paper
• Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

  2015cited by this paper
• Emerging targeted agents in metastatic breast cancer

  2013cited by this paper
• Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers?

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

  2012cited by this paper
• Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

  2012cited by this paper
• S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

  2011cited by this paper
• Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

  2011cited by this paper
• Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

  2010cited by this paper
• Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

  2009cited by this paper
• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  2007cited by this paper
• The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

  2006cited by this paper
• Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

  2006cited by this paper
• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  2005cited by this paper
• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  2005cited by this paper
• The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

  2003cited by this paper
• Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

  2003cited by this paper
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

  2001cited by this paper
• A flexible design for multiple armed screening trials

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.

  1999cited by this paper

• Why Does EGFR-Targeted Therapy Continue to Fail in Breast Cancer? From Mechanistic Deciphering to Novel Intervention Strategies.

  2026cites this paper
• Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms

  2025cites this paper
• 4-octyl itaconate inhibits high glucose induced renal tubular epithelial cell fibrosis through TGF-β-ROS pathway

  2024cites this paper
• Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities.

  2024cites this paper
• Busting the Breast Cancer with AstraZeneca's Gefitinib

  2023cites this paper
• Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines

  2022cites this paper
• The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature

  2022cites this paper
• Beyond HER2: Targeting the ErbB receptor family in breast cancer.

  2022cites this paper
• Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment

  2021cites this paper
• Tyrosine kinase inhibitors in breast cancer (Review).

  2021cites this paper
• Art of prevention: The importance of dermatologic care when using aromatase inhibitors

  2021cites this paper
• Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

  2021cites this paper
• Nuclear receptors: lipid and hormone sensors with essential roles in the control of cancer development.

  2020cites this paper
• The efficacy of gefitinib supplementation for breast cancer

  2020cites this paper
• Methylcrotonoyl-CoA carboxylase 2 overexpression predicts an unfavorable prognosis and promotes cell proliferation in breast cancer.

  2019cites this paper
• CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer

  2019cites this paper
• Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

  2019cites this paper
• Tyrosine Kinase Inhibitors

  2019cites this paper
• A meta-analysis of randomized controlled studies

  2019influential citation
• Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole – First Case Report and another Example of an Immunocompromised District

  2018cites this paper
• Developing a novel strategy to treat glioblastoma : improving brain bioavailability of sorafenib with a synthetic flavonoid dimer to inhibit drug efflux in blood brain barrier

  2018influential citation
• Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

  2018cites this paper
• Optimising endocrine therapy in postmenopausal women with advanced breast cancer.

  2018cites this paper
• Rhamnetin induces apoptosis in human breast cancer cells via the miR-34a/Notch-1 signaling pathway.

  2018cites this paper
• Gefitinib inhibits retina angiogenesis by affecting VEGF signaling pathway.

  2018cites this paper
• Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen.

  2017cites this paper
• New agents for endocrine resistance in breast cancer.

  2017cites this paper
• Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors

  2017cites this paper
• Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.

  2017cites this paper
• Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.

  2017cites this paper
• Endocrine Therapies in the Adjuvant and Advanced Disease Settings

  2017cites this paper
• Treatment for the endocrine resistant breast cancer: Current options and future perspectives.

  2017cites this paper
• Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy

  2017cites this paper
• Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer

  2016cites this paper
• Endocrine treatment in breast cancer: Cure, resistance and beyond.

  2016cites this paper
• ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy

  2016cites this paper
• Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance

  2016cites this paper